New pill for Kids' eczema itch shows promise in large trial

NCT ID NCT01840605

Completed Symptom relief Sponsor: Tanabe Pharma Corporation Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a new oral medicine called TAU-284 (bepotastine besilate) can reduce itching in children aged 7 to 15 with atopic dermatitis (eczema). Over 300 children took either TAU-284 or an older medicine (ketotifen) twice daily for several weeks. The main goal was to see if TAU-284 works as well as ketotifen at easing itch severity.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bepotastine besilate (TAU-284)
What this could lead to: If successful, this could provide a new oral option to reduce itching in children with eczema.
What could go wrong: This is a completed Phase 3 trial, but results may show it is no better than existing treatments. It only targets itching, not the underlying disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema atopic IgE-mediated allergic disorder dermatitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS

Contacts and locations

Show contact details

Locations

Medical Corporation Kojinkai Asanuma Dermatology Clinic

Hokkaido, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.